Last reviewed · How we verify
felodipin
Felodipine, marketed by Sahlgrenska University Hospital, is a calcium channel blocker indicated for the treatment of hypertensive disorder. The drug's key strength lies in its well-established mechanism and market presence, with a key composition patent expiring in 2028. The primary risk is the potential increase in generic competition following the patent expiry in 2028.
At a glance
| Generic name | felodipin |
|---|---|
| Sponsor | Sahlgrenska University Hospital |
| Target | Aldehyde oxidase, Adenosine receptor A3, Cytochrome P450 2C9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Hypertensive disorder
Common side effects
- Peripheral edema
- Headache
- Flushing
Serious adverse events
- Myocardial infarction
- Syncope
- Angioedema
- Hypotension
- Angina pectoris
- Arrhythmia
- Leukocytoclastic vasculitis
- Chest pain
- Facial edema
- Anemia
Key clinical trials
- Copenhagen Acute Renal Complications After Transplantations Study Group (PHASE4)
- Blood Pressure Lowering Effect of Transcutaneous Electrical Nerve Stimulation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- felodipin CI brief — competitive landscape report
- felodipin updates RSS · CI watch RSS
- Sahlgrenska University Hospital portfolio CI